BLA 761033 · Teva Respiratory LLC
Cinqair
Reslizumab · Injection · Interleukin-5 Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Jan 9, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Mar 23, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
13 Phase 3, 2 recruiting
FAERS reports
688
443 serious, 17 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ANAPHYLAXIS Anaphylaxis has been observed with CINQAIR infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of CINQAIR [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6 )] . Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after CINQAIR administration by a healthcare professional prepared to manage anaphylaxis. Discontinue CINQAIR immediately if the patient experiences signs or symptoms of anaphylaxis [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.1 )] . WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning. Anaphylaxis occurred with CINQAIR infusion in 0.3% of patients in placebo-controlled studies ( 5.1 ) Patients should be observed for an appropriate period of time after CINQAIR infusion; healthcare...
What it is approved for
From the label in effect Feb 29, 2020.
CINQAIR ® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies ( 14 )] . Limitation of Use: CINQAIR is not indicated for treatment of other eosinophilic conditions. CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . CINQAIR is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype ( 1 ). Limitations of Use : CINQAIR is not indicated for: treatment of other eosinophilic conditions ( 1 ) relief of acute bronchospasm or status asthmaticus ( 1 )
Mechanism: Reslizumab is an interleukin-5 antagonist (IgG4, kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Reslizumab binds to IL-5 with a dissociation constant of 81 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil surface. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids,...
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 23, 2016 Original approval · Type 1 - New Molecular Entity NovelSummary ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- CINQAIR · RESLIZUMAB 100MG/10ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Reslizumab" as an intervention, any sponsor and status, largest first.
- Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaPivotal-lookingTerminated
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01290887 · 1,052 participants · Start Jun 2011 · Primary completion Jan 2015
Drug: Reslizumab · For: Eosinophilic Asthma
Sites: Scottsdale, Arizona; Anaheim, California; Fountain Valley, California · 219 sites in all
- Cross-sectional Study for Identification and Description of Severe Asthma PatientsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02293265 · 767 participants · Start Dec 2014 · Primary completion May 2015
Drug: Short Acting Beta Agonist (SABA) · For: Asthma
Sites: Little Rock, Arkansas; Fresno, California; Los Angeles, California · 74 sites in all
- Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01508936 · 511 participants · Start Feb 2012 · Primary completion Aug 2013
Drug: Reslizumab; Placebo · For: Eosinophilic Asthma
Sites: Birmingham, Alabama; Homewood, Alabama; Jasper, Alabama · 66 sites in all
- A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01287039 · 489 participants · Start Apr 2011 · Primary completion Dec 2013
Drug: Reslizumab; Placebo · For: Eosinophilic Asthma
Sites: Scottsdale, Arizona; Los Angeles, California; Orange, California · 128 sites in all
- Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood EosinophilsPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT02452190 · 468 participants · Start Sep 28, 2015 · Primary completion Dec 4, 2017
Drug: Reslizumab; Placebo · For: Asthma
Sites: Birmingham, Alabama; Flagstaff, Arizona; Glendale, Arkansas · 226 sites in all
- A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01285323 · 464 participants · Start Mar 2011 · Primary completion Apr 2014
Drug: Reslizumab; Placebo · For: Eosinophilic Asthma
Sites: Mobile, Alabama; Fresno, California; Long Beach, California · 104 sites in all
- A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic AsthmaPivotal-lookingTerminated
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT03052725 · 391 participants · Start Mar 10, 2017 · Primary completion Feb 22, 2018
Drug: reslizumab · For: Eosinophils, Asthma
Sites: Birmingham, Alabama; Bakersfield, California; Huntington Beach, California · 134 sites in all
- A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01270464 · 315 participants · Start Feb 2011 · Primary completion Sep 2013
Drug: Reslizumab; Placebo · For: Eosinophilic Asthma
Sites: Anaheim, California; Fountain Valley, California; Los Angeles, California · 89 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea96
- asthma95
- incorrect dose administered88
- drug ineffective83
- hypertension73
- cough47
- headache43
- wheezing40
- fatigue39
- pneumonia33
- inappropriate schedule of product administration32
- oropharyngeal pain31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 19 |
| 2017 | 90 |
| 2018 | 93 |
| 2019 | 58 |
| 2020 | 66 |
| 2021 | 72 |
| 2022 | 76 |
| 2023 | 45 |
| 2024 | 55 |
| 2025 | 73 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cinqair (Reslizumab)
2024 spending
$962K
Beneficiaries
26
237 claims
Per beneficiary
$37,010
$106.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $889,073 |
| 2021 | $1,039,210 |
| 2022 | $860,241 |
| 2023 | $955,768 |
| 2024 | $962,250 |
Part B: Cinqair (Reslizumab) · HCPCS J2786
2024 spending
$8.6M
Beneficiaries
302
2,890 claims
Per beneficiary
$28,477
2024 ASP limit $10.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,663,482 |
| 2021 | $11,402,565 |
| 2022 | $11,088,289 |
| 2023 | $9,788,941 |
| 2024 | $8,600,043 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I, Beltran J, Akdis C, et al. · Allergy 2020 · Systematic Review
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
Charles D, Shanley J, Temple SN, et al. · Clin Exp Allergy 2022 · Meta-Analysis, Systematic Review
- Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis.
Chen ML, Nopsopon T, Akenroye A · J Allergy Clin Immunol Pract 2023 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
Phinyo P, Krikeerati T, Vichara-Anont I, et al. · J Allergy Clin Immunol Pract 2024 · Systematic Review, Network Meta-Analysis
- Biologic Management in Severe Asthma for Adults: An American College of Chest Physicians Clinical Practice Guideline.
Oberle AJ, Abbas F, Adrish M, et al. · Chest 2026 · Systematic Review, Practice Guideline
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, Zangrilli J, Wechsler ME, et al. · Lancet Respir Med 2015 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.